Stock Scorecard



Stock Summary for Rigel Pharmaceuticals (RIGL) - $45.69 as of 11/13/2026 2:33:54 PM EST

Total Score

13 out of 30

Safety Score

33 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for RIGL

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for RIGL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for RIGL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for RIGL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for RIGL (33 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for RIGL

Morgan Stanley reports a passive stake above 5% in Rigel Pharmaceuticals (RIGL). 11/14/2026 5:31:00 AM
Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Aren't As Good As They Appear 11/12/2026 12:58:00 PM
Form SCHEDULE 13G RIGEL PHARMACEUTICALS Filed by: STATE STREET CORP 11/10/2026 2:12:00 PM
State Street reports a Rigel Pharmaceuticals (RIGL) stake with shared voting power over 858,066 shares. 11/10/2026 2:12:00 PM
Missed Out On Rigel Pharmaceuticals' Run? Here's What Changed 11/10/2026 3:23:00 AM
Citigroup maintains Rigel Pharmaceuticals at Buy, raises price target to $86 from $83 11/9/2026 5:54:00 PM
Key facts: Rigel Posts $80.9M Q3 Revenue; Cantor Raises Price Target to $47 11/7/2026 8:28:00 AM
Rigel Pharmaceuticals Q3 Earnings Call Highlights 11/6/2026 11:00:00 PM
Rigel Pharmaceuticals Inc (RIGL) (Q3 2026) Earnings Call Highlights: Record Product Sales of ... 11/6/2026 7:14:00 PM
Rigel Pharmaceuticals (RIGL) Misses Q3 EPS by 25c 11/6/2026 5:28:00 AM

Financial Details for RIGL

Company Overview

Ticker RIGL
Company Name Rigel Pharmaceuticals
Country N/A
Description Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2026
Next Earnings Date N/A

Stock Price History

Last Day Price 45.69
Price 4 Years Ago 15.00
Last Day Price Updated 11/13/2026 2:33:54 PM EST
Last Day Volume 151,387
Average Daily Volume 245,503
52-Week High 52.60
52-Week Low 24.95
Last Price to 52 Week Low 83.13%

Valuation Measures

Trailing PE N/A
Industry PE 48.09
Sector PE 51.83
5-Year Average PE 6.99
Free Cash Flow Ratio 18.42
Industry Free Cash Flow Ratio 18.18
Sector Free Cash Flow Ratio 32.69
Current Ratio Most Recent Quarter 2.39
Total Cash Per Share 2.48
Book Value Per Share Most Recent Quarter 23.70
Price to Book Ratio 1.78
Industry Price to Book Ratio 4.44
Sector Price to Book Ratio 11.41
Price to Sales Ratio Twelve Trailing Months 2.87
Industry Price to Sales Ratio Twelve Trailing Months 24.06
Sector Price to Sales Ratio Twelve Trailing Months 21.39
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 18,830,000
Market Capitalization 860,342,700
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 1.33%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -55.50%
Annual Earnings Growth 1,999.08%
Reported EPS 12 Trailing Months 16.07
Reported EPS Past Year 1.97
Reported EPS Prior Year 6.49
Net Income Twelve Trailing Months 307,194,000
Net Income Past Year 367,024,000
Net Income Prior Year 17,485,000
Quarterly Revenue Growth YOY 16.50%
5-Year Revenue Growth 22.06%
Operating Margin Twelve Trailing Months 21.10%

Balance Sheet

Total Cash Most Recent Quarter 46,646,000
Total Cash Past Year 40,580,000
Total Cash Prior Year 56,746,000
Net Cash Position Most Recent Quarter 31,655,000
Net Cash Position Past Year 18,098,000
Long Term Debt Past Year 22,482,000
Long Term Debt Prior Year 52,408,000
Total Debt Most Recent Quarter 14,991,000
Equity to Debt Ratio Past Year 0.95
Equity to Debt Ratio Most Recent Quarter 0.97
Total Stockholder Equity Past Year 391,480,000
Total Stockholder Equity Prior Year 3,288,000
Total Stockholder Equity Most Recent Quarter 445,107,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 89,693,000
Free Cash Flow Per Share Twelve Trailing Months 4.76
Free Cash Flow Past Year 75,655,000
Free Cash Flow Prior Year 31,075,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -1.05
MACD Signal -0.19
20-Day Bollinger Lower Band 35.95
20-Day Bollinger Middle Band 44.41
20-Day Bollinger Upper Band 52.87
Beta 1.24
RSI 42.19
50-Day SMA 38.12
150-Day SMA 25.42
200-Day SMA 22.30

System

Modified 11/14/2026 6:20:57 AM EST